Parameter
| Biomarker | ER | Full name | Estrogen receptor | Molecular Type | Protein |
|---|---|---|---|---|---|
| Molecular Formula | / | Molecular Weight | / | Core Functional Dimensions | Diagnosis, prognosis |
| Disease | Breast Cancer | Disease Subtypes | / | ||
| Organ | Breast | Test Sample / Technology Platform | Tumor tissue (IHC, immunofluorescence IF) | ||
| Pathobiological Mechanisms | When ER binds to estrogen, it activates downstream signaling pathways and promotes abnormal proliferation of breast epithelial cells. This is the core driving mechanism of hormone receptor-positive breast cancer. | ||||
| Clinical Availability Status | Clinical routine (recommended by guidelines): IHC testing is the gold standard for breast cancer classification, guiding the selection of endocrine therapy (such as tamoxifen, aromatase inhibitors). | ||||
| Notes and Dynamics | Patients with low expression of ER have a lower response rate to endocrine therapy. The new SERD (selective estrogen receptor degrader) is effective for some patients who are resistant to treatment. | ||||